Vaxil’s products are derived from its fully owned proprietary technology VaxHit, which uses the Signal Peptide domains in selected targets as core antigens.

Vaxil’s lead product, ImMucin [EMA and FDA Orphan drug designated for the treatment of multiple myeloma cancer], composed of the entire SP domain of the MUC1 tumor associated antigen. ImMucin has successfully completed, a Phase I/II clinical trial in 15 MM patients demonstrating a high safety profile, robust immunity and initial hints for clinical efficacy. Vaxil is currently performing an additional Phase I/II study with ImMucin in metastatic breast cancer patients being treated with 1st line hormonal therapy.

Vaxil also isolated SPmAb-2.1 and SPmAb-6, the only anti-MUC1 SP antibodies harboring superior therapeutic and diagnostic properties vs. other MUC1 antibodies.

Vaxil further validated its VaxHit technology for anti-infective indications, isolated MTBuVax, a multi-antigenic multi-epitope sub-unit LP vaccine against mycobacterium Tuberculosis currently in pre-clinical animal studies.

The company was founded in early 2007 by an experienced management team supported by leading scientists and clinicians.






Israeli based Vaxil BioTherapeutics (Vaxil), a fully owned subsidiary of Vaxil Bio Ltd. (TASE: VAXL), is a clinical stage biotechnology company developing novel, immunotherapeutic products, both long peptides  vaccines and antibodies to treat cancer and infectious diseases.